How Can Low-Income Patients Afford Egrifta (Tesamorelin)?

Why Egrifta Costs So Much

Brand-name Egrifta carries a wholesale acquisition cost that places it among the most expensive daily-injection peptides on the U.S. market. Theratechnologies holds the sole NDA for tesamorelin, and the drug's orphan-like patient population (FDA approval is limited to HIV-associated lipodystrophy) means pricing reflects a small commercial base rather than broad-market competition 1.

Without insurance, patients report cash-pay quotes between $3,200 and $3,800 per month depending on pharmacy. The absence of a generic bioequivalent keeps competitive downward pressure minimal. Specialty pharmacies that stock Egrifta typically require enrollment in a hub program before dispensing, which adds administrative delays but also opens the door to financial assistance pathways.

A 2019 analysis in the Journal of Managed Care & Specialty Pharmacy found that specialty drugs with limited-population indications averaged 22% higher per-unit costs than those with broad indications, even after adjusting for manufacturing complexity 2. Egrifta fits this pattern precisely. The monthly cost exceeds median U.S. rent in most states, making unassisted access impossible for patients living below or near the federal poverty level.

Theratechnologies Patient Assistance Program

Theratechnologies operates a dedicated patient assistance program (PAP) for Egrifta that provides the drug at no cost to qualifying patients. Eligibility centers on household income, insurance status, and residency.

Patients must be U.S. residents, lack adequate prescription drug coverage for Egrifta, and have household income at or below 300% of the federal poverty level (approximately $46,800 for an individual or $96,000 for a family of four in 2026). The application requires proof of income (tax return or pay stubs), a signed prescription from a licensed provider, and documentation of insurance denial or lack of coverage 3.

Processing typically takes 2 to 4 weeks. Once approved, patients receive a 90-day supply shipped directly to their provider's office or home address. Renewals require annual re-certification of income.

One limitation: the PAP excludes patients enrolled in any federal healthcare program, including Medicaid, Medicare Part D, or TRICARE. Patients on these programs must pursue separate avenues described below.

Copay Cards and Manufacturer Coupons

For commercially insured patients whose plan covers Egrifta but imposes high cost-sharing, Theratechnologies offers a copay assistance card. This program can reduce monthly out-of-pocket costs to as little as $0 for eligible patients, with a maximum annual benefit that typically caps between $10,000 and $15,000.

Eligibility requires active commercial (private) insurance that covers Egrifta. Patients with government-funded insurance (Medicare, Medicaid, VA, TRICARE) are excluded by federal anti-kickback statute requirements. The card activates at the point of sale through the specialty pharmacy's billing system.

To enroll, patients or their providers call the Egrifta support hub and provide insurance details. Activation is usually same-day. The card renews annually and requires re-verification of insurance status.

One important nuance: copay card spending does not always count toward a plan's annual out-of-pocket maximum. Under accumulator adjustment programs adopted by some PBMs, the manufacturer's contribution may be excluded from deductible calculations, leaving the patient responsible for the full deductible after the card's benefit exhausts 4. Patients should ask their insurer directly whether copay card payments apply to their deductible and out-of-pocket maximum before relying on this pathway alone.

Compounded Tesamorelin as a Lower-Cost Alternative

Compounded tesamorelin represents the most significant cost reduction available. Through FDA-registered 503B outsourcing facilities, compounding pharmacies produce tesamorelin acetate at approximately $350 per month, a reduction exceeding 90% compared to brand Egrifta 5.

The legal framework: Section 503B of the Federal Food, Drug, and Cosmetic Act allows outsourcing facilities to compound drugs without individual prescriptions, provided they register with the FDA, follow current good manufacturing practices (cGMP), and submit to regular inspections. Tesamorelin produced under these conditions is not FDA-approved but is legally dispensable by licensed prescribers.

Key differences between compounded and brand-name tesamorelin:

Purity and potency verification. Brand Egrifta undergoes full NDA-level batch testing. Compounded versions follow cGMP but with less regulatory oversight on long-term stability data. Patients should confirm their pharmacy holds active 503B registration and request recent certificates of analysis.

Insurance coverage. Compounded tesamorelin is almost never covered by insurance. Patients pay cash. This paradoxically makes it more accessible for uninsured or underinsured patients who cannot manage prior authorization.

Clinical equivalence. No head-to-head trials compare compounded tesamorelin to brand Egrifta. The active molecule is identical, but excipients, reconstitution protocols, and storage requirements may differ. Prescribers should monitor clinical response (waist circumference, visceral adipose tissue on imaging) after switching.

For patients earning above the PAP income threshold but unable to afford $3,500 monthly, compounded tesamorelin at $350 per month is often the most practical route. Many telehealth platforms and hormone optimization clinics now prescribe compounded tesamorelin for both on-label and off-label (body composition) uses.

Insurance Coverage and Prior Authorization

When insurance does cover Egrifta, approval almost always requires prior authorization documenting HIV-associated lipodystrophy with objective evidence of excess visceral adiposity.

Standard prior authorization criteria include: confirmed HIV diagnosis, documented trunk fat accumulation (CT or DEXA showing elevated visceral adipose tissue), and failure of or contraindication to lifestyle modification. Some plans additionally require a minimum CD4 count or viral load suppression on antiretroviral therapy 6.

The initial approval in the key Phase III trial (N=816) demonstrated that tesamorelin 2 mg daily reduced trunk fat by 15.2% versus 4.9% increase with placebo at 26 weeks, establishing the efficacy basis that formulary committees reference 6.

Denial rates and appeals. First-line denials are common. The most frequent denial reasons are: lack of documentation proving lipodystrophy diagnosis, failure to demonstrate medical necessity beyond cosmetic concern, and step-therapy requirements. A peer-to-peer review between the prescribing physician and the plan's medical director succeeds in overturning denials approximately 40 to 60% of the time when supported by imaging evidence.

Off-label coverage. For patients seeking tesamorelin for non-HIV indications (GH-axis optimization, MASLD fat reduction, body composition), insurance coverage is extremely rare. The AACE 2024 guidelines do not include tesamorelin in standard metabolic treatment algorithms for non-HIV patients 7. These patients should plan for self-pay through compounding or PAP alternatives.

State Pharmaceutical Assistance Programs (SPAPs)

Forty-three states operate some form of pharmaceutical assistance program for residents who fall into coverage gaps. These programs vary enormously in eligibility, covered drug lists, and benefit structure.

For tesamorelin specifically, the most relevant SPAPs are those linked to HIV/AIDS Drug Assistance Programs (ADAPs), administered through the Health Resources and Services Administration's Ryan White HIV/AIDS Program 8. ADAP covers antiretrovirals and related medications for low-income people living with HIV who are uninsured or underinsured.

Whether ADAP covers Egrifta depends on the individual state's formulary. As of early 2026, coverage varies:

• Some state ADAPs include Egrifta on their formularies for patients meeting lipodystrophy criteria
• Others exclude it as non-essential or refer patients to the manufacturer PAP
• A few states cover it through supplemental funding or 340B drug pricing arrangements

Patients should contact their state ADAP coordinator (directory available through HRSA at hab.hrsa.gov) to determine local formulary status 9. Income thresholds for ADAP eligibility typically range from 200% to 500% FPL depending on the state.

340B Drug Pricing for Eligible Facilities

The 340B Drug Pricing Program requires manufacturers participating in Medicaid to sell outpatient drugs at significantly reduced prices to covered entities serving low-income populations. Eligible entities include federally qualified health centers (FQHCs), Ryan White clinics, disproportionate share hospitals, and certain community health centers 10.

For Egrifta, 340B pricing can reduce acquisition cost by 25 to 50% below wholesale. Patients receiving care at a 340B-covered entity may access the drug at reduced or no cost depending on the entity's sliding-fee scale. This pathway works for patients enrolled in Medicaid or Medicare who cannot use the manufacturer copay card.

The key requirement: the patient must receive care and the prescription from a provider within a 340B-registered entity. Transferring a prescription to an outside pharmacy typically disqualifies the 340B discount. Patients should ask their HIV care provider whether their clinic participates in 340B.

Navigating the Application Process Step by Step

A structured approach prevents delays and denials:

Step 1: Determine insurance status. If commercially insured with Egrifta coverage, start with the copay card. If uninsured or denied, proceed to the PAP. If on Medicaid/Medicare, check ADAP and 340B eligibility.

Step 2: Gather documentation. All pathways require: current prescription for tesamorelin 2 mg daily, proof of diagnosis (HIV lipodystrophy documentation or off-label clinical rationale), income verification (most recent tax return or two months of pay stubs), and insurance denial letter (if applicable).

Step 3: Submit through the prescriber. Most PAP applications must be initiated by the prescribing provider's office. Patients should provide all documentation to their clinical team and request submission. Self-submission is not accepted for most programs.

Step 4: Follow up at 2-week intervals. Applications stall most often due to missing documentation. Calling the support hub every 14 days ensures progress and catches requests for additional information early.

Step 5: If denied, appeal or pivot. PAP denials based on income can sometimes be appealed with documentation of extraordinary medical expenses reducing effective income. Insurance denials should trigger a formal appeal with peer-to-peer review. If all else fails, compounded tesamorelin at $350 per month remains available without insurance or program enrollment.

Comparing All Access Pathways

The right pathway depends on insurance status, income, and diagnosis:

Uninsured, income below 300% FPL, HIV lipodystrophy diagnosis: Manufacturer PAP (free drug).

Commercially insured, Egrifta on formulary, high copay: Copay assistance card ($0, $50/month).

Medicare/Medicaid, HIV diagnosis, treated at 340B entity: 340B pricing through the clinic's pharmacy.

Any income, any insurance status, willing to self-pay: Compounded tesamorelin ($300, $450/month depending on pharmacy and dose).

State ADAP-eligible, HIV diagnosis: Check state formulary for Egrifta inclusion before pursuing other pathways.

For patients using tesamorelin off-label (non-HIV body composition, GH-axis support, or MASLD), the realistic options narrow to compounded tesamorelin or full cash-pay brand. Neither manufacturer PAP nor insurance coverage typically applies to off-label use.

Timeline Expectations

From initial prescription to first injection, realistic timelines vary by pathway:

• Copay card activation: 1 to 3 days
• Insurance prior authorization (first attempt): 5 to 15 business days
• Insurance appeal after denial: 30 to 60 days
• Manufacturer PAP approval: 2 to 4 weeks
• ADAP enrollment: 2 to 6 weeks depending on state
• Compounded pharmacy order: 3 to 7 business days

Patients facing urgent clinical need should consider starting with compounded tesamorelin while PAP or insurance applications process in parallel. There is no medical reason to delay treatment initiation while awaiting financial assistance decisions, provided the patient can temporarily cover the compounded cost.